These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 14534919)

  • 61. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A double-blind study of bromocriptine and L-dopa in de novo Parkinson's disease. Short-term results.
    Riopelle RJ; Gawel MJ; Libman I; King DB; McLean DR; Paulseth R; Raphy B; Bouchard S
    Eur Neurol; 1988; 28 Suppl 1():11-4. PubMed ID: 3288477
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
    Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W
    Eur J Neurol; 2013 Jan; 20(1):180-7. PubMed ID: 22845710
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.
    Pfeiffer RF; Gutmann L; Hull KL; Bottini PB; Sherry JH;
    Parkinsonism Relat Disord; 2007 Mar; 13(2):93-100. PubMed ID: 17055329
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.
    Bara-Jimenez W; Bibbiani F; Morris MJ; Dimitrova T; Sherzai A; Mouradian MM; Chase TN
    Mov Disord; 2005 Aug; 20(8):932-6. PubMed ID: 15791634
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
    Noyes K; Dick AW; Holloway RG;
    Pharmacoeconomics; 2005; 23(12):1257-70. PubMed ID: 16336019
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005).
    LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM;
    Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease A short commentary.
    Quinn NP
    J Neurol; 2003 Jan; 250(1):97. PubMed ID: 12528000
    [No Abstract]   [Full Text] [Related]  

  • 70. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 71. The initial treatment of Parkinson's disease should begin with levodopa.
    Weiner WJ
    Mov Disord; 1999 Sep; 14(5):716-24. PubMed ID: 10495031
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study.
    Rektorová I; Rektor I; Bares M; Dostál V; Ehler E; Fanfrdlová Z; Fiedler J; Klajblová H; Kulist'ák P; Ressner P; Svátová J; Urbánek K; Velísková J
    Eur J Neurol; 2003 Jul; 10(4):399-406. PubMed ID: 12823492
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease.
    Uchiyama T; Sakakibara R; Yamamoto T; Ito T; Yamaguchi C; Awa Y; Yano M; Yanagisawa M; Kobayashi M; Higuchi Y; Ichikawa T; Yamanishi T; Hattori T; Kuwabara S
    Mov Disord; 2009 Dec; 24(16):2386-90. PubMed ID: 19908315
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo-controlled study.
    da Silva-Júnior FP; Braga-Neto P; Sueli Monte F; de Bruin VM
    Parkinsonism Relat Disord; 2005 Nov; 11(7):449-52. PubMed ID: 16154788
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study).
    Oertel WH; Stiasny-Kolster K; Bergtholdt B; Hallström Y; Albo J; Leissner L; Schindler T; Koester J; Reess J;
    Mov Disord; 2007 Jan; 22(2):213-9. PubMed ID: 17133582
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease.
    Stacy M; Silver D; Mendis T; Sutton J; Mori A; Chaikin P; Sussman NM
    Neurology; 2008 Jun; 70(23):2233-40. PubMed ID: 18519872
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
    Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
    Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.